IBD Maintenance Therapy: Positioning Biologics in the Biologic Era

Clinical Practice Update — Positioning Anti-TNF, Anti-Integrin, Anti-IL-23, and JAK Inhibitor Therapies in Adults

This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.

MDA-IBD-2026 · 14 min read
Clinical Focus
Positioning biologics and small molecules for moderate-to-severe Crohn’s disease and ulcerative colitis in adults
Target Audience
Gastroenterologists, internists, hospitalists, IBD nurse specialists, residents, advanced practice providers
Setting
Outpatient gastroenterology, infusion centres, primary care follow-up
Source Evidence
  • •AGA Clinical Practice Guideline on Moderate-to-Severe Ulcerative Colitis (2020)
  • •ACG Clinical Guideline: Management of Crohn’s Disease in Adults (2018)
  • •ECCO Guidelines on Crohn’s Disease and Ulcerative Colitis (2022–2024)
  • •SEAVUE Trial (ustekinumab vs adalimumab, Crohn’s, Lancet 2022)
  • •VARSITY Trial (vedolizumab vs adalimumab, UC, NEJM 2019)
  • •ADVANCE / MOTIVATE / FORTIFY Trials (risankizumab, Crohn’s, Lancet 2022)
  • •OCTAVE Trials (tofacitinib, UC, NEJM 2017)
  • •U-EXCEL / U-EXCEED Trials (upadacitinib, Crohn’s, NEJM 2023)
  • •STRIDE-II Selecting Therapeutic Targets in IBD (Gastroenterology 2021)

Key Clinical Takeaways

Effective IBD maintenance therapy in adults now spans four mechanistic classes — anti-TNF, anti-integrin, anti-IL-23, and JAK inhibitors — each with a distinct evidence base, safety profile, and clinical niche. The points below distill current evidence into actionable rules for positioning these agents in moderate-to-severe Crohn’s disease and ulcerative colitis.

Positioning algorithm for IBD maintenance therapy showing anti-TNF, anti-integrin, anti-IL-23, and JAK inhibitor options in adults
Mechanistic classes available for adult IBD maintenance therapy and their typical positioning in clinical practice.
  1. 1Match the agent to disease phenotype, severity, prior biologic exposure, and patient comorbidity — there is no single best drug across all patients → Choosing First-Line
  2. 2Reserve infliximab as the preferred first-line agent in fistulizing or perianal Crohn’s disease → Choosing First-Line
  3. 3Consider vedolizumab as a preferred first-line option in moderate-to-severe ulcerative colitis given its favourable safety profile → Choosing First-Line
  4. 4Position IL-23 inhibitors (risankizumab, mirikizumab, guselkumab) for biologic-naive or anti-TNF-experienced patients with luminal disease → Anti-IL-23 Positioning
  5. 5Restrict JAK inhibitors (tofacitinib, upadacitinib) primarily to patients who have failed an anti-TNF agent, and counsel on FDA boxed warnings → JAK Inhibitor Positioning
  6. 6Use therapeutic drug monitoring to guide anti-TNF dosing — subtherapeutic troughs and anti-drug antibodies explain most secondary loss of response → Sequencing
  7. 7Treat to a composite target of steroid-free clinical remission plus endoscopic and biomarker remission, not symptoms alone → Treat-to-Target
  8. 8Reassess every patient on IBD maintenance therapy at least annually, even when in remission → Monitoring
  9. 9Complete latent infection screening and vaccinations before starting any biologic or JAK inhibitor — do not delay urgent therapy for routine immunisations → Pre-Treatment

Pre-Treatment Assessment Before Starting Maintenance Therapy

Every patient about to begin IBD maintenance therapy needs a standardised pre-treatment workup. The goal is to identify latent infections that may reactivate, update vaccinations that will not be possible later (especially live vaccines), and align therapy with reproductive goals.

1

Perform latent tuberculosis screening with an interferon-gamma release assay (or tuberculin skin test if IGRA unavailable) and a chest radiograph before any biologic or JAK inhibitor.

Strong Rec High Evidence AGA 2020 ECCO 2024
2

Test for hepatitis B (HBsAg, anti-HBc, anti-HBs), hepatitis C antibody, and HIV before initiating maintenance therapy — reactivation of occult hepatitis B with anti-TNF and JAK inhibitors is well described.

Strong Rec High Evidence ACG 2018 ECCO 2024
3

Complete any indicated live attenuated vaccines (MMR, varicella, zoster live) at least four weeks before starting biologic or JAK therapy. Once therapy begins, live vaccines are generally avoided.

Strong Rec Moderate Evidence ACG 2018
4

Administer inactivated vaccines (annual influenza, pneumococcal series, hepatitis B if non-immune, HPV if eligible, COVID-19 boosters, recombinant zoster vaccine) either before therapy or alongside it — do not delay urgent biologic initiation for routine inactivated vaccination.

Strong Rec High Evidence ACG 2018
5

Discuss pregnancy planning early, ideally at the time of agent selection. Most monoclonal antibody biologics (anti-TNF, vedolizumab, ustekinumab) are considered low risk in pregnancy; JAK inhibitors and methotrexate are contraindicated.

Strong Rec Moderate Evidence ECCO 2023
6

Counsel every patient on smoking cessation. The benefit is especially large in Crohn’s disease, where continued smoking accelerates disease progression and reduces response to maintenance therapy.

Strong Rec High Evidence ECCO 2022
7

Obtain baseline labs including complete blood count, comprehensive metabolic panel, CRP, and fecal calprotectin to establish reference values for future monitoring of IBD maintenance therapy response.

Strong Rec Low Evidence Expert Consensus
Clinical Pearl: If a patient with severe active disease cannot wait the four weeks needed for live vaccines, prioritise disease control. Live vaccines can be deferred, but uncontrolled inflammation cannot wait.

Choosing First-Line IBD Maintenance Therapy

Selecting first-line IBD maintenance therapy now means choosing among at least four mechanistic classes. The right choice depends on disease type (Crohn’s vs ulcerative colitis), disease behaviour (luminal vs fistulizing), severity, comorbidities, prior exposure, and patient preference around route and frequency of administration.

Ulcerative Colitis

8

Start vedolizumab 300 mg intravenous at weeks 0, 2, and 6, then every 8 weeks, as a preferred first-line option in biologic-naive adults with moderate-to-severe ulcerative colitis — supported by the VARSITY head-to-head trial demonstrating superiority over adalimumab for clinical remission at week 52.

Strong Rec High Evidence AGA 2020 VARSITY 2019
9

Initiate infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks, as the preferred first-line maintenance after rescue therapy for acute severe ulcerative colitis. Higher induction doses (10 mg/kg) may be needed in patients with severe inflammation and rapid drug clearance.

Strong Rec High Evidence AGA 2020 ECCO 2022
10

Consider mirikizumab or risankizumab as IL-23 inhibitor options for moderate-to-severe ulcerative colitis, particularly in patients who prefer subcutaneous self-administration and a non-anti-TNF mechanism.

Moderate Rec High Evidence LUCENT 2023
11

Prescribe adalimumab 160 mg week 0, 80 mg week 2, then 40 mg every other week, as an alternative subcutaneous first-line option in moderate ulcerative colitis when an anti-TNF is preferred and intravenous infusion is impractical.

Moderate Rec High Evidence AGA 2020

Crohn’s Disease

12

Prescribe infliximab as the preferred first-line maintenance therapy in fistulizing or perianal Crohn’s disease. Anti-TNF agents are the only class with consistent randomised evidence for perianal fistula closure.

Strong Rec High Evidence ACG 2018 ECCO 2024
13

Start risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg subcutaneous every 8 weeks, as a first-line option in moderate-to-severe luminal Crohn’s, including biologic-experienced patients — supported by ADVANCE, MOTIVATE, and FORTIFY.

Strong Rec High Evidence ADVANCE 2022 FORTIFY 2022
14

Consider ustekinumab as a first-line option in biologic-naive moderate-to-severe Crohn’s disease — the SEAVUE head-to-head trial showed broadly comparable clinical remission at one year with adalimumab and a favourable safety profile.

Moderate Rec High Evidence SEAVUE 2022
15

Consider vedolizumab in patients with luminal Crohn’s at elevated infection or malignancy risk where a gut-selective mechanism is desirable. Onset of action is slower than anti-TNF, so it is less suited to patients needing rapid symptom control.

Conditional Rec Moderate Evidence GEMINI 2 2013
16

Prescribe adalimumab 40 mg subcutaneous every other week as an alternative first-line maintenance for moderate luminal Crohn’s when subcutaneous self-administration is preferred and immunogenicity risk is considered acceptable.

Moderate Rec High Evidence ACG 2018

Combination Therapy With Immunomodulators

17

Consider combining infliximab with a thiopurine (azathioprine or 6-mercaptopurine) or methotrexate during the first 6–12 months to reduce immunogenicity and improve durable response — benefit demonstrated most clearly with infliximab in Crohn’s (SONIC trial).

Moderate Rec High Evidence SONIC 2010
18

Avoid long-term thiopurine plus anti-TNF combination therapy in young men because of the rare but reported risk of hepatosplenic T-cell lymphoma. Methotrexate is a reasonable alternative immunomodulator in this group.

Conditional Rec Low Evidence ACG 2018

Sequencing IBD Maintenance Therapy After Loss of Response

Most patients on IBD maintenance therapy will eventually experience loss of response. The first step is always to confirm active inflammation rather than functional symptoms, and then to characterise the mechanism of failure — subtherapeutic drug exposure, immunogenicity, or true mechanistic non-response.

19

Confirm active inflammation with objective markers (fecal calprotectin, CRP, endoscopy or cross-sectional imaging) before changing IBD maintenance therapy. Symptoms alone are insufficient because IBS-like symptoms, bile salt diarrhoea, and small bowel bacterial overgrowth can mimic flare.

Strong Rec Moderate Evidence STRIDE-II 2021
20

Use therapeutic drug monitoring to measure trough drug levels and anti-drug antibodies in patients losing response to an anti-TNF. Most secondary failure has a pharmacokinetic explanation that can be addressed without switching class.

Strong Rec High Evidence AGA 2017
21

Optimise the dose (shorten the interval or increase the per-dose amount) when anti-TNF trough levels are subtherapeutic and anti-drug antibodies are absent or low-titre.

Strong Rec Moderate Evidence AGA 2017
22

Switch within the anti-TNF class (e.g., infliximab to adalimumab) when failure is driven by high-titre anti-drug antibodies. Adding an immunomodulator at switch can reduce repeat immunogenicity.

Moderate Rec Moderate Evidence AGA 2017
23

Switch out-of-class for primary non-response (no response within an adequate induction interval despite adequate drug exposure). A different mechanism is more likely to succeed than another agent in the same class.

Strong Rec Moderate Evidence ECCO 2024
24

Evaluate for non-inflammatory contributors (C. difficile, CMV in steroid-refractory UC, strictures, abscess, NSAID use, undiagnosed bile salt diarrhoea) before assuming a true biologic failure.

Strong Rec High Evidence ACG 2018
Clinical Pearl: Before declaring an anti-TNF failure, ensure adequate drug exposure was actually achieved. Many “failures” are really under-dosing in patients with high inflammatory burden and rapid drug clearance.

JAK Inhibitor Positioning

JAK inhibitors (tofacitinib, upadacitinib, filgotinib) are oral small molecules with rapid onset and broad efficacy across IBD subtypes. After the ORAL Surveillance trial in rheumatoid arthritis, the FDA applied class-wide boxed warnings for major adverse cardiovascular events, venous thromboembolism, serious infections, malignancy, and all-cause mortality. These warnings shape current positioning.

25

Reserve tofacitinib for moderate-to-severe ulcerative colitis after failure or intolerance of at least one anti-TNF agent. Use 10 mg twice daily for induction, then step down to 5 mg twice daily for maintenance once response is achieved.

Moderate Rec High Evidence OCTAVE 2017 FDA 2021
26

Consider upadacitinib 45 mg daily induction, then 15–30 mg daily maintenance, for moderate-to-severe ulcerative colitis or Crohn’s disease after anti-TNF failure — supported by U-ACHIEVE and U-EXCEL/U-EXCEED.

Moderate Rec High Evidence U-EXCEL 2023
27

Counsel patients on the class-wide FDA boxed warnings before starting a JAK inhibitor — particularly major adverse cardiovascular events, venous thromboembolism, malignancy, and serious infection. Document the discussion.

Strong Rec High Evidence FDA 2021
28

Avoid JAK inhibitors as the first agent of choice in patients aged 65 or older with cardiovascular risk factors, current or past smokers, prior thromboembolism, or prior malignancy — particularly when an effective biologic alternative exists.

Against Moderate Evidence FDA 2021 ORAL Surveillance
29

Step down to the lowest effective JAK inhibitor maintenance dose once remission is achieved. The dose-related signal for adverse events makes this especially relevant for tofacitinib at 10 mg twice daily.

Strong Rec Moderate Evidence FDA Label 2021
30

Administer recombinant zoster vaccine before starting a JAK inhibitor whenever feasible — zoster reactivation rates are higher with JAK inhibitors than with anti-TNF or other biologic classes.

Strong Rec Moderate Evidence ACG 2018
Warning
JAK inhibitors carry FDA boxed warnings for major adverse cardiovascular events, venous thromboembolism, serious infection, malignancy (including lymphoma), and all-cause mortality. These risks are most pronounced in patients aged 50 or older with at least one cardiovascular risk factor, especially current or past smokers.

Clinical Decision Pathway

A practical, question-based approach for positioning IBD maintenance therapy in adults with moderate-to-severe disease. Work through the questions in order.

Positioning the First Maintenance Agent: 5 Questions
Question 1: Is this Crohn’s disease with fistulizing or perianal involvement?
Yes → Anti-TNF (infliximab preferred). Combine with surgical drainage of any abscess.
No → Continue to Question 2.
Question 2: Is this moderate-to-severe ulcerative colitis in a biologic-naive patient?
Yes → Vedolizumab is a preferred first-line option (VARSITY supports superiority over adalimumab).
Anti-TNF (infliximab) is preferred after rescue therapy for acute severe ulcerative colitis.
Question 3: Is this luminal Crohn’s disease in a biologic-naive patient?
Risankizumab, ustekinumab, or anti-TNF are all reasonable first-line options.
Favour risankizumab or ustekinumab when infection or malignancy risk is elevated.
Question 4: Has the patient failed an anti-TNF?
Confirm true failure with therapeutic drug monitoring and active inflammation on biomarkers or endoscopy.
UC → vedolizumab, mirikizumab, ustekinumab, tofacitinib, or upadacitinib.
Crohn’s → risankizumab, ustekinumab, vedolizumab, or upadacitinib.
Question 5: Does the patient have any features that should steer away from a JAK inhibitor?
Age 65+, prior MACE, prior VTE, active or recent malignancy, or current smoker → favour a biologic over a JAK inhibitor.
None of these → JAK inhibitor is a reasonable option after anti-TNF failure if an oral agent with rapid onset is preferred.

Practical Tables

Maintenance Agents by Drug Name — Dosing, Niche, and Cautions

DrugMaintenance DoseBest Suited ForKey Cautions
Infliximab (anti-TNF)5 mg/kg IV every 8 weeks (escalate to 10 mg/kg or q4w if needed)Fistulizing CD, post-ASUC maintenanceImmunogenicity; combine with immunomodulator early
Adalimumab (anti-TNF)40 mg SC every 2 weeks (weekly if needed)Moderate CD/UC, SC preferenceInjection-site reactions; immunogenicity
Vedolizumab (anti-integrin)300 mg IV every 8 weeks (or 108 mg SC q2w)Biologic-naive UC; gut-selective when systemic risk is highSlower onset; less effective for extraintestinal disease
Ustekinumab (anti-IL-12/23)90 mg SC every 8 weeks (shorten to q4w if needed)Biologic-naive CD; UC; favourable safety profileSingle IV induction is logistical step
Risankizumab (anti-IL-23p19)360 mg SC every 8 weeks (CD); 180/360 mg SC q8w (UC)Moderate-severe CD including biologic-experiencedNewer agent; long-term safety data still maturing
Mirikizumab (anti-IL-23p19)200 mg SC every 4 weeks (UC)Moderate-severe UCSC-only induction; relatively new in clinical practice
Tofacitinib (JAK inhibitor)5 mg PO twice daily (10 mg BID if needed)UC after anti-TNF failure; oral preferenceFDA boxed warnings; avoid in high CV/VTE risk
Upadacitinib (JAK1 selective)15–30 mg PO dailyUC and CD after anti-TNF failureFDA boxed warnings; check lipids and herpes zoster status

Sequencing After Failure of First-Line IBD Maintenance Therapy

Failure PatternLikely MechanismFirst ActionWhen to Switch Class
Anti-TNF, low trough, no antibodiesUnder-dosing or rapid clearanceDose-optimise (shorten interval or escalate dose)If still failing after adequate optimisation
Anti-TNF, high-titre antibodiesImmunogenic loss of responseSwitch to a second anti-TNF + immunomodulatorIf second anti-TNF also fails
Primary non-response, adequate exposureTrue mechanistic failureSwitch class (different mechanism)Immediately
Vedolizumab/ustekinumab loss of responseLess immunogenic; usually pharmacodynamicShorten interval (q4w) before switchingIf interval shortening fails after 3 months
Symptoms but normal biomarkersOften functional, bile salts, SIBO, NSAIDEvaluate non-inflammatory causesOnly after objective inflammation confirmed

Treat-to-Target Monitoring on IBD Maintenance Therapy

Symptom-only follow-up under-detects ongoing inflammation. Modern IBD maintenance therapy aims for a composite of steroid-free clinical remission, biomarker normalisation, and endoscopic healing, with adjustments driven by objective data.

31

Target steroid-free clinical remission, normalisation of CRP and fecal calprotectin, and endoscopic remission as the composite goal of IBD maintenance therapy.

Strong Rec Moderate Evidence STRIDE-II 2021
32

Reassess at 3 months, 6 months, and 12 months after initiating or switching therapy, then at least annually. Earlier reassessment is appropriate after any flare.

Strong Rec Low Evidence STRIDE-II 2021
33

Measure fecal calprotectin every 3–6 months in patients on maintenance therapy. A persistent value above approximately 250 μg/g is suggestive of ongoing inflammation and warrants further evaluation.

Strong Rec Moderate Evidence ECCO 2022
34

Perform endoscopic reassessment 6–12 months after starting a new agent for moderate-severe disease, then per long-term surveillance schedule.

Moderate Rec Moderate Evidence STRIDE-II 2021
35

Check CBC, comprehensive metabolic panel, and CRP every 3–6 months on long-term maintenance therapy. Add lipid panel and herpes zoster status check periodically for patients on JAK inhibitors.

Strong Rec Low Evidence Expert Consensus
Clinical Pearl: A patient still on steroids beyond 3 months has, by definition, failed steroid-sparing. Plan the corticosteroid taper at the same visit as biologic initiation, not later.

Evidence in Context

What the major head-to-head trials show, and where AGA, ACG, and ECCO guidance align or diverge.

VARSITY: Vedolizumab vs Adalimumab in Ulcerative Colitis
In the first major head-to-head biologic trial in UC, intravenous vedolizumab produced higher rates of clinical remission at one year than subcutaneous adalimumab. The result reshaped first-line positioning in moderate-to-severe UC and is a major reason vedolizumab is now considered a preferred first-line option in biologic-naive patients.
SEAVUE: Ustekinumab vs Adalimumab in Biologic-Naive Crohn’s
SEAVUE compared ustekinumab and adalimumab head-to-head in biologic-naive moderate-to-severe Crohn’s disease. Clinical remission rates at one year were broadly similar, but ustekinumab had fewer serious adverse events. The trial supports either agent as a reasonable first-line option, with selection driven by safety and preference.
Rise of IL-23 Inhibitors in Crohn’s Disease
Risankizumab demonstrated significant efficacy in moderate-to-severe Crohn’s disease across the ADVANCE (biologic-naive), MOTIVATE (biologic-experienced), and FORTIFY (maintenance) trials. IL-23p19 selective inhibition has emerged as a preferred non-anti-TNF option for both biologic-naive and biologic-experienced luminal Crohn’s, broadening the IBD maintenance therapy toolkit.
JAK Inhibitors: ORAL Surveillance and the FDA Boxed Warning
The ORAL Surveillance trial of tofacitinib in rheumatoid arthritis patients aged 50 or older with at least one cardiovascular risk factor showed elevated rates of MACE, malignancy, and all-cause mortality compared with anti-TNF. In 2021 the FDA extended boxed warnings to the JAK class, including tofacitinib and upadacitinib used in IBD. Current positioning generally reserves JAK inhibitors for patients who have failed an anti-TNF.
Where AGA, ACG, and ECCO Align and Diverge
All three frameworks now endorse positioning by safety profile and head-to-head data rather than rigid step-up sequencing. AGA places vedolizumab and infliximab among preferred first-line options in moderate-to-severe UC. ECCO emphasises mechanism-of-failure-based switching after anti-TNF loss of response. ACG retains a stronger role for combination therapy with thiopurines in selected patients, while ECCO has moved toward monotherapy with optimised dosing as the long-term standard.

References

  1. 1.Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–1461. doi:10.1053/j.gastro.2020.01.006
  2. 2.Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. doi:10.1038/ajg.2018.27
  3. 3.Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (VARSITY). N Engl J Med. 2019;381(13):1215–1226. doi:10.1056/NEJMoa1905725
  4. 4.Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus Adalimumab for Induction and Maintenance Therapy in Biologic-Naive Patients with Moderately to Severely Active Crohn’s Disease (SEAVUE). Lancet. 2022;399(10342):2200–2211. doi:10.1016/S0140-6736(22)00688-2
  5. 5.D’Haens G, Panaccione R, Baert F, et al. Risankizumab as Induction Therapy for Crohn’s Disease (ADVANCE and MOTIVATE). Lancet. 2022;399(10340):2015–2030. doi:10.1016/S0140-6736(22)00467-6
  6. 6.Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (OCTAVE Induction 1, 2, and Sustain). N Engl J Med. 2017;376(18):1723–1736. doi:10.1056/NEJMoa1606910
  7. 7.Loftus EV, Panes J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease (U-EXCEL and U-EXCEED). N Engl J Med. 2023;388(21):1966–1980. doi:10.1056/NEJMoa2212728
  8. 8.Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031

How to Read the Evidence Tags

Every recommendation in this article carries simplified inline tags for recommendation strength and evidence quality — Medaptly’s own interpretation rather than any single guideline body’s classification.

Recommendation Strength

TagWhat It Means
Strong RecHigh-quality evidence broadly supports this action across guidelines.
Moderate RecThe weight of evidence favours the action, with reasonable variation in practice.
Conditional RecBenefit is less certain — individualise to patient and context.
AgainstEvidence shows no benefit or potential harm; the action should generally be avoided.

Evidence Quality

TagWhat It Means
High EvidenceMultiple well-designed randomised controlled trials or high-quality meta-analyses.
Moderate EvidenceSingle RCT or large observational studies with consistent findings.
Low EvidenceExpert consensus or small studies; clinical judgement matters most here.

Article Information

For Educational Purposes Only. This is original clinical education content informed by current published guidelines and trial evidence. It does not constitute medical advice, is not endorsed by any guideline body, and does not replace individualised clinical judgement, local formulary guidance, or specialist input. Drug indications, doses, and monitoring requirements vary by region and prescribing label, and biologic landscape evolves rapidly — verify all prescribing decisions against the current product label and applicable regulatory guidance. Patients with IBD should be co-managed with a gastroenterologist experienced in advanced therapies. Readers are encouraged to consult the original source guidelines and clinical trial publications listed in References.
The Medaptly Digest

Stay current in your specialty.

The evidence that moved practice this week — guideline shifts, landmark trials, and cases worth a second look — in a few high-yield minutes.

Free · One issue a week · Unsubscribe anytime

Which specialties?

Pick the ones you want — choose as many as you like.

Your newsletters

RELATED CONTENT

Explore More in This Specialty

Handpicked content from across articles, cases, research, guidelines, news, and presentations.

Loading related content...